Evolution of easi response with lebrikizumab in patients with moderate-to- severe atopic dermatitis: pooled results from two phase 3 trials (advocate1 and advocate2) at week 16
ACTA DERMATO-VENEREOLOGICA(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要